Cite
HARVARD Citation
Kato, K. et al. (n.d.). 785TiPPhase III KEYNOTE-590 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer. Annals of oncology. p. . [Online].